News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Not Moving Forward With Onyx Pharmaceuticals, Inc. (ONXX) Bid: Sources


7/19/2013 7:04:01 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Pfizer Inc decided not to pursue a bid for Onyx Pharmaceuticals Inc this week, according to two people familiar with the matter, leaving Amgen Inc in the front position to buy the cancer drugmaker. Shares of Onyx closed down 3.3 percent at $128.55 on Thursday, their lowest level since it announced a sale process on June 30 and valuing the South San Francisco, California-based company at around $9.3 billion. Onyx, which rejected Amgen's $120 per share bid and instead put itself up for sale, was expecting to receive first-round offers from a few interested parties as soon as this week, people familiar with the matter previously told Reuters.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at News Release
Read at Street Insider
Read at Daily Finance


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES